ReviewAdvances in clinical chemistry2025
The cancer microbiome.
Review in Advances in clinical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The cancer microbiome is an emerging concept that is referred to as the microorganism communities associated with cancer. There has been controversy in terms of the bona fide functions of the microbiome in carcinogenesis and cancer development, since the microorganisms were first observed within tumor tissues. Recently, there has been growing evidence showing that the microbiome indeed plays a role in cancer initiation, development, diagnosis, and treatment through diverse mechanisms and interactions between host cells and microbes. Rather than contaminants or artifacts, the cancer microbiome has been proven to be alive in the tumor microenvironment and possess significantly differential physiological and morphological properties compared to the corresponding environmental microorganisms. However, due to the low abundance of microbes within cancer tissues (especially the intratumoral microbiota) and lack of efficient analytical tools (e.g., sensitive antibodies, sensors, and probes), there are still a number of challenges and question marks in this fast-growing field. In this chapter, we made a systematic summary of the cancer microbiome, specifically focusing on its discovery and the recent research advances with respect to the studies on its functions and corresponding technology development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.